Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer. (16th March 2021)

• Record Type: Journal Article
• Authors: Yamashita, Takuya; Shiota, Masaki; Machidori, Asako; Kobayashi, Satoshi; Matsumoto, Takashi; Monji, Keisuke; Kashiwagi, Eiji; Takeuchi, Ario; Takahashi, Ryosuke; Inokuchi, Junichi; Shiga, Ken-ichiro; Yokomizo, Akira; Eto, Masatoshi
• Is Part Of: Cancer investigation. Volume 39:Number 3(2021)
• Page Start: 251
• Page End: 256
• Publication Date: 2021-03-16
• Subjects: Castration-resistant prostate cancer -- docetaxel -- treatment schedule -- adverse event; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2020.1871486
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m 2 ) between 2008 and 2018 were included. Among 125 Japanese men, 40 (32.0%) and 85 (68.0%) were treated with 3-weekly and 4-weekly regimens, respectively. In the 4-weekly regimen, the risks of progression, treatment failure, and any-cause mortality were comparable to those in the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. These data suggest that the 4-weekly regimen may be an acceptable option for selected patients.